Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. NASDAQ:RNAC
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Cartesian Therapeutics announces additional Descartes-08 retreatment data for myasthenia gravis
The company said Descartes-08 showed a mean MG-ADL reduction of 6.6 points at month 12 post-retreatment, with median retreatment interval of 16.6 months. It reported no new safety signals and said Phase 3 Aurora topline is expected in 1Q27, with an NDA filing expected mid-2027.